Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of B-hHER2 EL4 Cells Induced Tumor Models (CAT#: STEM-AE-0171-LGZ)

Introduction

The mouse Erbb2 gene was replaced by human ERBB2 coding sequence in B-hHER2 EL4 cells. Human HER2 is highly expressed on the surface of B-hHER2 EL4 cells.<br />B-hHER2 EL4 cells have the capability to establish tumors in vivo and can be used for efficacy studies.CD340, HER-2, ERBB2<br />Common name: B-hHER2 EL4<br />Aliases: CD340, HER-2, ERBB2<br />Organism: Mouse<br />Tissue types: Lymphoma<br />Disease: Lymphoma<br />Strain: C57BL/6N <br />Tissue: T lymphocyte




Principle

Tumor-associated antigen (TAA) refers to antigen molecules that are specific or highly expressed in Tumor cells but absent or underexpressed in healthy cells, and are involved in the proliferation, differentiation, and migration of tumor cells. This makes TAA a potential effective molecular target of antitumor drugs. Taa-targeted drugs can kill tumor cells by mediating ADCC, CDC, and activating immune response. For this type of drug, subcutaneous inoculation of wild-type mice or in situ inoculation of humanized mouse cell lines can be used to evaluate its efficacy. We have developed a series of humanized cell lines for pharmacodynamic evaluation based on the current market demand for TAA target drug development. Some of the TAA targets are expressed in healthy tissues and cells and play important physiological functions. The drugs of these targets may have serious toxic and side effects, so we can provide the corresponding humanized animal models for drug safety evaluation.

Applications

Lymphoma

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder
Advertisement